Background
Results and discussion
Selection of autoimmune diseases
Disease term | Reports in VAERS | Top three vaccines reported (Number of reports) | ||
---|---|---|---|---|
Guillain-Barre Syndrome (GBS) | 1991 | Flu (1201) | Flu H1N1 (144) | Hepatitis (127) |
Rheumatoid Arthritis (RA) | 403 | Hepatitis (109) | Lyme (84) | Flu (47) |
Systemic Lupus Erythematosus (SLE) | 210 | Hepatitis (90) | Human Papillomavirus (36) | Flu (23) |
Idiopathic Thrombocytopenic Purpura (ITP) | 180 | Measles, Mumps & Rubella (64) | Varicella (46) | Flu (36) |
Others (N = 39) | 786 |
Data collection and curation
GAD | IEDB | KEGG | OMIM | PS | UniProt | Unique to source | |
---|---|---|---|---|---|---|---|
GAD
|
174
|
8
|
32
|
17
|
95
|
28
|
71
|
IEDB
|
156
|
13
|
3
|
45
|
23
|
93
| |
KEGG
|
172
|
4
|
67
|
21
|
89
| ||
OMIM
|
40
|
19
|
18
|
17
| |||
PS + Curation
|
621
|
50
|
434
| ||||
UniProt
|
112
|
38
|
Functional analysis and classification
Rheumatoid arthritis | Systemic lupus erythematosus | Immune thrombocytopenic purpura | Guillain-barre syndrome | |
---|---|---|---|---|
Number of Genes Associated >>
| 667 | 448 | 49 | 73 |
v Categories v
| ||||
Antigen Processing & Presentation |
6.30%
|
9.15%
|
14.29%
|
8.22%
|
Antimicrobials |
19.64%
|
17.19%
|
28.57%
|
39.73%
|
BCR Signaling Pathway |
2.85%
|
2.23%
|
6.12%
|
4.11%
|
Cytokines + Receptors |
28.49%
|
18.97%
|
30.61%
|
24.66%
|
> Chemokines + Receptors |
7.05%
|
3.79%
| 4.08% |
5.48%
|
> Interferons + Receptors | 0.30% | 0.67% | 4.08% |
4.11%
|
> Interleukins + Receptors |
5.55%
|
4.02%
|
8.16%
| 5.48% |
> TGF-b Family Members + Receptors |
1.20%
| 0.45% | 2.04% |
2.74%
|
> TNF Family Members + Receptors |
3.00%
|
2.90%
|
4.08%
| 1.37% |
Natural Killer Cell Cytotoxicity |
6.45%
|
6.47%
|
12.24%
|
9.59%
|
TCR Signaling Pathway |
4.50%
|
4.46%
|
10.20%
|
10.96%
|
Other Immune-Related |
28.94%
|
29.46%
| 34.69% | 19.18% |
Immune Disease Pathways |
19.34%
|
31.47%
|
38.78%
|
28.77%
|
Infectious Disease Pathways |
28.79%
|
29.46%
|
34.69%
|
45.21%
|
Unclassified |
16.49%
|
19.20%
|
8.16%
|
17.81%
|
RA | SLE | ITP | GBS | All four AIDs | |
---|---|---|---|---|---|
Cytotoxic T cell (n = 13)
|
7
|
8
|
1
|
1
|
7
|
Exhausted T cell (n = 7)
|
4
|
5
|
0
|
0
|
6
|
Anergic T cell (n = 11)
|
4
|
2
|
0
|
0
|
5
|
TR1 cell (n = 9)
|
4
|
4
|
1
|
2
|
5
|
Natural TReg cell (n = 15)
|
8
|
8
|
2
|
3
|
9
|
Inducible TReg cell (n = 17)
|
8
|
8
|
2
|
3
|
9
|
NKT cell (n = 10)
|
6
|
5
|
2
|
1
|
10
|
CD8αα
T cell (n = 10)
|
7
|
7
|
1
|
1
|
8
|
CD4+ αβ
T cell (n = 10)
|
3
|
4
|
1
|
1
|
4
|
CD8+ αβ
T cell (n = 9)
|
3
|
4
|
0
|
0
|
3
|
TH1 cell (n = 14)
|
8
|
9
|
3
|
4
|
10
|
TH 2 cell (n = 19)
|
8
|
8
|
2
|
2
|
10
|
TH 9 cell (n = 8)
|
3
|
4
|
1
|
2
|
4
|
TH 17 cell (n = 20)
|
11
|
5
|
1
|
1
|
12
|
TH 22 cell (n = 8)
|
3
|
3
|
1
|
1
|
4
|
TFH cell (n = 16)
|
9
|
10
|
2
|
3
|
13
|
Central memory T cell (n = 18)
|
7
|
10
|
3
|
1
|
10
|
Effector memory T cell (n = 8)
|
2
|
5
|
0
|
0
|
5
|
γδ T cell (n = 10)
|
5
|
4
|
1
|
1
|
7
|